Clinical Trials Logo

Chronic Kidney Disease clinical trials

View clinical trials related to Chronic Kidney Disease.

Filter by:

NCT ID: NCT03621176 Completed - Clinical trials for Chronic Kidney Disease

Home-based Exercise in Chronic Kidney Disease

HBCKD-BCN
Start date: August 1, 2018
Phase: N/A
Study type: Interventional

A home-based exercise program will be implemented in three different groups of participants: advanced chronic kidney disease, end-stage renal disease in substitutive treatment hemodialysis or peritoneal dialysis. Participants will be evaluated before the program, after 3 months and after 6 months from the starting of the program. During the first 3 months the researcher will phone them weekly to reinforce the exercise habit, and during the last three months, there will be no reinforcement. Assessment will include strength, functional capacity, health-related quality of life and depressive symptoms.

NCT ID: NCT03581071 Completed - Clinical trials for Chronic Kidney Disease

Clinical Pharmacology Study of TS-143 in Nondialysis and Hemodialysis Patients With Chronic Kidney Disease

Start date: October 6, 2016
Phase: Phase 1
Study type: Interventional

To evaluate the safety, pharmacokinetics, and pharmacodynamics in nondialysis (ND) and hemodialysis (HD) subjects with Chronic Kidney Disease (CKD) who receive a single administration of TS-143.

NCT ID: NCT03579693 Completed - Clinical trials for Chronic Kidney Disease

Trial of Nicotinamide Riboside and Co-enzyme Q10 in Chronic Kidney Disease

CoNR
Start date: November 14, 2018
Phase: Phase 2
Study type: Interventional

Chronic kidney disease is associated with the loss of skeletal muscle mass and function. This process detrimentally impacts mobility, functional independence, and quality of life. Mounting evidence suggests that chronic kidney disease impairs skeletal muscle functioning by injuring mitochondria, the central energy producing units of cells. Potential treatment options to restore mitochondrial function include aerobic and weight bearing exercise and medications that directly improve mitochondrial energetics. Unfortunately, exercise programs may be difficult to implement in people who have chronic diseases, such as kidney disease.. Coenzyme Q10 (coQ10) and nicotinamide riboside (NR) are naturally occurring supplements that can directly improve mitochondrial efficiency. Both compounds help mitochondria produce more energy while generating less waste. The primary purpose of this study is to test whether coQ10 and NR can improve muscle function among people with chronic kidney disease. What we learn in this study may help us better understand the mechanisms of skeletal muscle impairment among people with kidney disease and ultimately improve their ability to be active and independent.

NCT ID: NCT03576716 Completed - Clinical trials for Chronic Kidney Disease

Clearance of 25-hydroxyvitamin D3 During Vitamin D3 Supplementation

CLEAR-PLUS
Start date: June 1, 2018
Phase: Phase 1
Study type: Interventional

The goal of this study is to determine how 25(OH)D3 clearance is affected by vitamin D3 supplementation using a gold standard pharmacokinetic approach.

NCT ID: NCT03525223 Completed - Clinical trials for Chronic Kidney Disease Requiring Chronic Dialysis

Modulation of Tissue Sodium in Hemodialysis Patients

Start date: May 15, 2018
Phase: N/A
Study type: Interventional

Salt (NaCl) intake is implicated in causing hypertension and cardiovascular disease, the commonest cause of death worldwide. The investigators recently established that Na+ is stored in tissues, bound to glycosaminoglycans (GAGs) in skin and muscle. The resulting local hypertonicity leads to immune cell-driven induction of local tissue electrolyte clearance via modulation of cutaneous lymph capillary density. To visualize these complex processes in man directly, the investigators established Na+ magnetic resonance imaging (23Na-MRI) and investigated Na+ stores in hemodialysis (HD) patients. Hemodialysis patients were sodium-"overloaded" and HD treatment lowered tissue Na+ stores in this study. The observed effects were highly variable and independent of Na+ or water removal from the body during a dialysis session. Tissue Na+ mobilization correlated with circulating vascular endothelial growth factor-C (VEGF-C). The investigators believe that excessive Na+ storage is a reversible condition and therefore susceptible for therapeutic interventions. The investigators hypothesize that lowering dialysate Na+ concentration may favorably affect accelerated tissue Na+ accumulation in hemodialysis patients. Besides, improved tissue Na+ storage, osmostress-induced as well as pro-inflammatory immune cell response should be affected by such a revised dialysis management.

NCT ID: NCT03520738 Completed - Clinical trials for Chronic Kidney Disease

Tissue-nonspecific Alkaline Phosphatase in Phosphate and Pyrophosphate Homeostasis.

PIPAL
Start date: May 15, 2018
Phase: N/A
Study type: Interventional

Vascular calcification is a common finding in chronic kidney disease and increases arterial stiffness leading to augmented cardiovascular morbidity. The calcification process is thoroughly regulated by pro and anticalcifying agents. The investigators hypothesize that imbalance in these compounds could depend on alkaline phosphatase activity. Therefore, the investigators will measure ALP activity, calcifications score, arterial stiffness and perform a bio-collection in monogenic rare diseases characterized by various levels of anticalcifying agents and in diverse CKD stages characterized by various levels of procalcifying compounds.

NCT ID: NCT03511924 Completed - Clinical trials for Chronic Kidney Disease Requiring Chronic Dialysis

Intradialytic Resistance Training in Haemodialysis Patients

IRTHEP
Start date: January 11, 2018
Phase: N/A
Study type: Interventional

The study will investigate the effects of an intradialytic resistance training on miRNA´s expression and muscle strength in haemodialysis patients.

NCT ID: NCT03472105 Completed - Clinical trials for Chronic Kidney Disease, Stage 3 (Moderate)

Short-term Effect of a New Nordic Renal Diet on Phosphorus Homeostasis in CKD Stage 3-4

Start date: February 1, 2017
Phase: N/A
Study type: Interventional

Hyperphosphatemia is a severe complication to chronic kidney disease (CKD) and is associated with increased risk of vascular calcification, cardiovascular morbidity and mortality. Early dietary intervention and improvement in dietary therapy might optimally reduce cardiovascular complications. For this purpose the investigators investigated patients with CKD stage 3-4, the participants dietary habits, developed a New Nordic Renal Diet and investigated the short term effect on phosphorus homeostasis.

NCT ID: NCT03451019 Completed - Clinical trials for Chronic Kidney Disease

Different Effects of Non-calcium Phosphate Binders on Serum Calcium

Start date: March 1, 2018
Phase: Phase 4
Study type: Interventional

Sevelamer hydrochloride (SE) can increase intestinal calcium absorption in contrast to lanthanum carbonate (LA). Study compared effect of LA and SE on serum and urine phosphate and calcium, and hormones regulating mineral-bone metabolism.

NCT ID: NCT03400228 Completed - Clinical trials for Chronic Kidney Disease

Effect of Probiotic Consumption on Chronic Kidney Disease

Start date: July 1, 2015
Phase: N/A
Study type: Interventional

Recent studies have demonstrated that the balance of intestinal microbiota is affected in chronic kidney disease (CKD), leading to a condition known as intestinal dysbiosis. These changes were associated with metabolic complications, accumulation of uremic toxins, inflammation, progression of CKD and cardiovascular risk. Measures with the aim of restore the balance of intestinal flora are suggested, such as the intake of probiotics composed of beneficial bacteria, but few studies have discussed the effect of these supplements in CKD. The present study aims to evaluate the effect of consumption of probiotics in factors associates with progression of CKD and cardiovascular risk. To such will be conducted a double-blind, placebo-controlled, and randomized clinical trial with 30 patients with CKD in stages 3-5, treated in ambulatories of Nephrology of the Hospital de Clínicas de Porto Alegre, independently of etiology and with steady renal function. Patients will be excluded whether in substitutive renal therapy, kidney transplant, on antimicrobial therapy or immunosuppressive agents in the last three months or with acute clinical events. The assessment will include clinical and nutritional parameters, estimated glomerular filtration rate, proteinuria, serum lipids, inflammatory factors, and bowel habits. The study protocol includes the recruitment of patients who will undergo to 4-week washout period. After patients will be randomized and provided with probiotic therapy (intervention group) or placebo (maltodextrin; control group) for 24 weeks. All patients will be instructed to consume 2 sachets/day of probiotic or placebo and receive nutritional advice. All data will be analysed by the principal investigator with the support of a trained statistician and the chief investigator. The statistical programme SPSS will be used.